Engaging vulnerable populations in research during periods of crisis, uncertainty, or social disruption is both essential and challenging. Vulnerable populations are often disproportionately affected by public health emergencies, natural disasters, economic instability, and social unrest. Yet these groups are frequently underrepresented in research, limiting the applicability and equity of scientific findings. Even under normal circumstances, they often face structural barriers to healthcare and research participation; during crises, these barriers often intensify.
Patient centricity is often associated with recruitment, study design, and the tools patients use directly. Those elements matter, but the patient experience is also shaped by the preparation, systems, and operational processes in motion inside the research site. Patients notice when appointments are well organized, expectations are clear, and coordinators are prepared. They also notice when inefficient processes or technology distract research professionals from meaningful conversations. Equipping research teams with the tools to remain present and responsive is essential to patient-centered research.
Every clinical researcher has seen it. A patient comes to a site visit. They describe their experience in detail—the fatigue that started three weeks ago, the way it is different from their usual tiredness, the moment it began affecting their ability to work, the fear underneath it all that the drug might not be working anymore. The coordinator listens, nods, and documents: “Patient reports fatigue. Grade 1. No change from baseline.” The nuance disappears. The timeline disappears. The context disappears. The fear—which might have been the most clinically important signal in the room—disappears entirely. This is narrative distortion. And it is happening in clinical trials every day, in ways that affect data quality, patient safety, and the integrity of the evidence we are building.
Artificial intelligence (AI) is viewed as a potentially transformative force in the development of new therapies and has helped accelerate the discovery of new molecules. AI is also proving to accelerate the conduct of trials—and not a moment too soon, as the bottleneck in research shifts downstream away from discovery to in-human trials still hampered by operational friction. Now, a new study from the Tufts Center for the Study of Drug Development, conducted in collaboration with Medable, has taken an important step toward gaining critical understanding about how AI can help improve drug development.
For organizations that handle private and protected data related to healthcare (and other sensitive economic sectors), information security is not just a federally mandated compliance requirement—it should be a core business principle. ISO/IEC 27001:2022 certification demonstrates commitment to upholding the highest standards of security, governance, and operational excellence. By aligning processes, controls, and governance framework with globally recognized best practices, organizations ensure the delivery of secure, trusted, and resilient digital and AI-powered solutions for their clients and partners.